Health Trials

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

ConditionObesity or Overweight
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-99
SponsorAmgen

About this trial

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

Eligibility criteria

Qualifiers

Body Mass Index (BMI) ≥ 25 at screening.

Weight loss of ≥ 10% on weekly GLP-1 RA.

Stable body weight.

Stable dose of GLP-1RA.

Disqualifiers

Obesity induced by other endocrine disorders (ex: Cushing's syndrome).

Previous or planned surgical, endoscopic or device-based treatment for obesity.

History of malignancy.

Type 1/Type 2 diabetes mellitus (DM).

Trial design

Treatments tested in this trial

  • Maridebart Cafraglutide

Treatment groups

300 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Amgen

Lead sponsor

Source ClinicalTrials.gov